Watch for Teva's launch timing and pricing strategy for DEGEVMA and PONLIMSI in the coming months, which will determine market share capture against Amgen's Xgeva and Prolia. Also monitor any patent litigation or biosimilar competition from other manufacturers (e.g., Sandoz, Celltrion) that could affect Teva's market penetration.
Price Chart
Executive Summary
Teva announced FDA approval of DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab) for preventing bone complications in advanced cancer, treating giant cell tumor of bone, and hypercalcemia of malignancy. This is Teva's second FDA-approved biosimilar in 2026, complementing PONLIMSI (denosumab-adet) approved in March 2026, and establishes a comprehensive denosumab biosimilar portfolio spanning both Xgeva and Prolia indications. Launch in the U.S. is anticipated in the coming months.
Key Facts
- FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab) on September 28, 2026.
- Indicated for prevention of bone complications in adults with advanced cancer that has spread to bone, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.
- Teva's second FDA-approved biosimilar in 2026; PONLIMSI (denosumab-adet) was approved in March 2026.
- Together, DEGEVMA and PONLIMSI establish a comprehensive U.S. denosumab biosimilar portfolio covering both Xgeva and Prolia indications.
- Launch in the U.S. anticipated in the coming months; DEGEVMA is already approved in the European Union.
Financial Impact
No revenue or market size figures stated in the filing. Biosimilar denosumab addresses a multi-billion-dollar oncology bone health market (Xgeva had ~$2B+ annual U.S. sales prior to biosimilar entry). Teva's second biosimilar approval in 2026 adds a second major revenue stream alongside PONLIMSI.
Risk Factors
- Biosimilar competition from other manufacturers could limit market share and pricing power.
- Patent litigation with Amgen (Xgeva/Prolia) could delay or restrict launch.
- Manufacturing or supply chain issues could delay commercialization.
- Adverse safety events or regulatory actions could impact uptake.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370248 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Institutional Cluster | $41.11 | awaiting T+60 | — | $39.95 (+2.82%) |
Oct 8, 2026 18d ago | 3 | $41.10 | awaiting T+60 | — | $39.95 (−2.80%) |
Oct 2, 2026 24d ago | Press Release | $39.53 | awaiting T+60 | — | $39.95 (+1.06%) |
Oct 2, 2026 24d ago | Press Release | $39.53 | awaiting T+60 | — | $39.95 (+1.06%) |
Sep 30, 2026 26d ago | Press Release | $39.31 | awaiting T+60 | — | $39.95 (+1.63%) |
Sep 28, 2026 28d ago | Press Release | $39.81 | awaiting T+60 | — | $39.95 (+0.35%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $39.95 (−0.67%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $39.95 (−0.67%) |
Sep 22, 2026 4w ago | Insider Cluster | $39.01 | awaiting T+60 | — | $39.95 (−2.41%) |
Sep 18, 2026 5w ago | Press Release | $40.05 | awaiting T+60 | — | $39.95 (−0.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers